Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

Clinical trial NCT06287398 · RECRUITING

Trial details

NCT number: NCT06287398
Sponsor: Australasian Leukaemia and Lymphoma Group
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

DLBCL - Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements DLBCL, Nos Genetic Subtypes High Grade B-Cell Lymphoma, Not Otherwise Specified Follicular Large Cell Lymphoma, Relapsed Follicular Large Cell Lymphoma

Start date: 2023-12-11
Primary completion: 2026-11-01
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.